medigraphic.com
Colegio de Medicina Interna de México.

2018, Number 2

<< Back Next >>

Med Int Mex 2018; 34 (2)

Platelet physiology, platelet aggregometry and their clinical usefulness

Gómez-Gómez B, Rodríguez-Weber FL, Díaz-Greene EJ

Language: Spanish
References: 117
Page: 244-263
PDF size: 1182.64 Kb.


ABSTRACT

Learning about platelet function and its impact on physiology and the generation of disease is important, as well as knowing how to interpret the study of aggregometry that is now necessary to integrate diagnoses and therapeutic management.


REFERENCES

  1. Bizzozero J. On a new blood particle and its role in thrombosis and blood coagulation. Virchows Arch B Cell Pathol Incl Mol Pathol 1882;90:261.

  2. Born GV. Aggregation of blood platelets by adenosine and its reversal. Nature 1962;194:927.

  3. George JN. Platelets. Lancet 2000;355:1531-1539.

  4. Kaushansky K. Thrombopoietin. N Engl J Med 1998;339:746- 754.

  5. Weiss JG. Anatomy and structural organization of the platelet. En: Colman RW, Hirsh JU, Marder VJ, et al, editors. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 3rd ed. Philadelphia: Lippincott, 1994;397-413.

  6. Ware JA, Coller BS. Platelet morphology, biochemistry and function. En: Beutler E, Lichtman MA, Coller BS, et al, editors. Williams Hematology, 5th ed. New York: McGraw- Hill, 1995;1161-1201.

  7. Mills DC. ADP receptors on platelets. Thromb Haemost 1996;76:835-856.

  8. Glennon R, Dukat M. Novel serotoninergic agents: 5-HT2. Serotonin ID Research Alert 1997;2:107-113.

  9. Johnson GJ. Platelet thromboxane receptors: biology and function. En: Rao G, Ed. Handbook of platelets physiology and pharmacology. Boston: Kluwer Academic Publishers, 1999;38-79.

  10. Shukla SD. Platelet activating factor and platelets. En: Rao G, Ed. Handbook of platelets physiology and pharmacology. Boston: Kluwer Academic Publishers, 1999;120-141.

  11. Clemetson KJ, Clemetson JM. Platelet collagen receptors. Thromb Haemost 2001;86:189-197.

  12. Bennet JSW. The molecular biology of platelets membrane proteins. Semin Hematol 1990;27:186-204.

  13. Clark EA, Brugge JS. Integrins and signal transduction pathways: the road taken. Science 1995;268:233-239.

  14. Nierodzki ML, Klepfish A, Karpatkin S. Role of platelet integrin GPIIb-GPIIIa, fibronectina, von Willebrand factor and thrombin in platelet-tumor interaction in vitro and metastasis in vivo. Semin Hematol 1994;31:278-288.

  15. López JA. The platelet glycoprotein Ib-IX complex. Blood Coagul Fibrinolysis 1994;5:97-119.

  16. Jurk K, Kehrel BE. Platelets: physiology and biochemistry. Semin Thromb Hemost 2005;31:381-392.

  17. Andrews RK, López JA, Berndt MC. Molecular mechanisms of platelet adhesion and activation. Int J Biochem Cell Biol 1997;29:91-105.

  18. Kroll MH, Hellums JD, McIntire LV, et al. Platelets and Shear stress. Blood 1996;88:1525-1541.

  19. Gibbins JM. Platelet adhesion signaling and the regulation of thrombus formation. J Cell Sci 2004;117:3415-3425.

  20. Hartwig JH. The platelet: form and function. Semin Hematol 2006;42:s94-100.

  21. Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost 2001;86:222-232.

  22. Savage B, Cattaneo M, Ruggeri ZM. Mechanisms of platelets aggregation. Curr Opin Hematol 2001;8:270-276.

  23. Jackson, SP. The growing complexity of platelet aggregation. Blood 2007;109:5087.

  24. Born GRV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927-029.

  25. Seegmiller A, Sarode R. Laboratory Evaluation of platelet function. Hematol Oncol Clin N Am 2007;21:731-742.

  26. Rodgers G. Qualitative platelet disorders and von Willebrand disease. En: Kjeldsberg CR, Ed. Practical diagnosis of hematologic disorders. 4th ed. Chicago: ASCP Press, 2006;327-344.

  27. Newhouse P, Clark C. The variability of platelet aggregation. En: Tripplet DA Ed. Platelet function: laboratory evaluation and clinical application. Chicago: ASCP, 1978;63-107.

  28. Rand ML, Leung R, Packham MA. Platelet function assays. Transfus Apher Scio 2003;28:307-127.

  29. Lecchi A, Zighetti ML, Lussana F, et al. Platelet aggregation studies: autologous platelet-poor plasma inhibits platelet aggregation when added to platelet-rich plasma to normalize platelet count. J Thromb Haemost 2005;3(Suppl 1):p0965.

  30. Bick RL. Platelet function defects. En: Bick RL, editor. Disorders of Thrombosis and Hemostasis: Clinical and Laboratory Practice. Lippincott Williams & Wilkins, 2002;59-90.

  31. Cardinal DC, Flower RJ. The electric aggregometer: a novel device for assessing platelet behavior in blood. J Pharmacol Methods 1980;3:135-158.

  32. Mackie IJ, Jones R, Machin SJ. Platelet impedance aggregation in whole blood assay and its inhibition by antiplatelet drugs. J Clin Pathol 1984;37:874.

  33. Ingerman-Wojenski CM, Silver MJ. A quick method for screening platelet dysfunction using the whole blood lumiaggregometer. Thromb Haemost 1984;51:154-156.

  34. Nicholson NS, Panzer-Knodle SG, Haas NF, et al. Assessment of platelet function assays. Am Heart J 1998;135:S170.

  35. Mascelli MA, Worley S, Veriabo NJ, et al. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-IIb/IIIa therapy. Circulation 1997;96:3860.

  36. Storey RF, May Ja, Wilcox RG, Heptinstall S. A whole blood assay of inhibition of platelet aggregation by glycoprotein IIb/ IIIa antagonists: comparison with other aggregation methodologies. Thromb Haemost 1999;82:1307.

  37. Dyszkiewicz-Korpanty AM, Frenkel EP, Sarode R. Approach to the assessment of platelet function: comparison between optical-based platelet-rich plasma and impedancebased whole blood platelet aggregation methods. Clin Appl Thromb Hemost 2005;11:25-35.

  38. Bick RL. Platelet function defects. Semin Thromb Hemost 1992;18:167-185.

  39. Bernard J, Soulier JP. Sur une nouvelle variete dystrophic thrombocytaire hemorrhagipase congenitale. Semin Hopitaux Paris 1948;24:2317.

  40. White JG. Inherited abnormalities of platelet membrane and secretory granules. Hum Pathol 1987;18:123-132.

  41. Bithel TC, Parokh SJ, Stronf RR. Platelet function in the Bernard- Soulier syndrome. Ann NY Acad Sci 1972;201:145-154.

  42. Howard MA, Hutton RA, Hardistry RM. Hereditary giant platelet syndrome: a new disorder of platelet function. Br Med J 1973;2:586-595.

  43. Bick RL. Hereditary coagulation protein defects. In: Disorders of thrombosis and hemostasis. Philadelphia: Lippincott Williams & Wilkins, 2002;117-1388.

  44. von Willebrand E. Hereditary pseudohaumofilie. Fin Lakaresallsk Handl 1926;68:87.

  45. Rodeghiero F, Castman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand’s disease. Blood 1987;69:454-460.

  46. Werner E, Broxson E, Tucker E, et al. Prevalence of von Willebrand’s disease in children: a multiethnic study. J Pediatr 1993;123-132.

  47. Batlle J, Torea J, Rendal E, at al. The problem of diagnosing von Willebrand’s disease. J Intern Med 1997;242(Suppl 749):121.

  48. Koedam JA, Meijers JC, Sixma JJ, et al. Inactivation of human factor VIII by activated protein C: cofactor activity of protein S and protective of von Willebrand factor. J Clin Invest 1988;82:1236-1254.

  49. Sadler J. A revised classification of von Willebrand disease: for the subcommittee on von Willebrand factor of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Thromb Haemost 1994;71:520-552.

  50. Glanzmann E. Hereditare hamorrhagische thrombastenic. Beitr Pathol Bluttplatt Jahrb Kinderheilkd 1918;88:1-15.

  51. Caen JP. Glanzmann thrombastenia. Clin Haematol 1972;1:383-390.

  52. Bick R, Murano L. Physiology of hemostasis. Clin Lab Med 1994;14:677-689.

  53. Inceman S, Tangun V. Essential athrombia. Thromb Diath Haemorrh 1975;33:278-287.

  54. Holmawn H, Weiss WH. Further evidence for a deficient storage pool of adenine nucleotides in platelets from some patients with thrombocytopathia: “storage pool disease”. Blood 1972;39:197-207.

  55. Pareti FI, Mannucci L, Capitanio L, et al. Heterogeneity of storage pool deficiency. Thromb Haemost 1977;38:3-15.

  56. Schetz MRC. Coagulation disorders in acute renal failure. Kidney Int 1998;53(Suppl 66):96.

  57. Horowitz HI, Cohen DB, Martinez P, et al. Defective ADP induced platelet factor 3 activation in uremia. Blood 1967;30:331-339.

  58. Horowitz HI, Stein IM, Cohen BD, et al. Further studies on the platelet-inhibiting affect of guanidino-succinic acid and its role in uremic bleeding. Am J Med 1970;49:339-348.

  59. Escolar G, Casa A, Bastidi E. Uremic platelets have a functional defect affecting the interaction of von Willebrand factor with glycoprotein IIb-IIIa. Blood 1990;76:1336.

  60. Komarnicki M, Twardowski T. Platelet glycoprotein concentrations in patients with chronic uraemia. Folia Haematol 1987;114:642.

  61. Mammen EF. Coagulopathies of liver disease. Clin Lab Med 1994;14:669-786

  62. Bick RL. The clinical significance of fibrinogen degradation products. Semin Thromb Hemost 1983;8:302-315.

  63. Ashud MA. Platelet size and number in alcoholic thrombocytopenia. N Engl J Med 1972;286:355-360.

  64. Cowan DH. Effect of alcoholism on Hemostasis. Semin Hematol 1980;17:137-149.

  65. Bick RL. Clinical aspects of acquired circulating anticoagulants. En: Bick RL, Bennett J, Brynes R, et al, editors. Hematology: clinical and laboratory practice. St. Louis: Mosby; 1993:1533.

  66. Bick RL, Strauss JF, Rutherford CJ, et al. Thrombosis and hemorrhage in oncology patients. Hematol Oncol Clin North Am 1996;10:875-890.

  67. Frenkel UP, Bick RL. Issues of thrombosis and hemorrhagic events in patients with cancer. Anticancer Res 1998;18:1-4.

  68. Lachner H. Hemostatic abnormalities associated with dysproteinemias. Semin Hematol 1973;10:125-141.

  69. Schafer AI. Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984;64:1-14.

  70. Raman BK, Van-Slyck EJ, Riddle J. Platelet function and structure in myeloproliferative disease, myelodisplastic syndrome and secondary thrombocytosis. Am J Clin Pathol 1989;91:647-659.

  71. Pflieger G, Boda Z, Udvardy M. Platelet function studies in myeloproliferative disorders. Folia Haematol 1986;113:655-670.

  72. Bick RL. Thrombotic and hemorrhagic problems during cardiovascular bypass surgery and cardiovascular procedures. En: Rodger L Bick. Disorders of Thrombosis and Hemostasis: Clinical and Laboratory Practice. Philadelphia: Lippincott Williams & Wilkins, 2002;177-212.

  73. Bick RL. Hemostasis defects in cardiac surgery and use of cardiac devices. En: Piffere R, editor. Cardiac surgery: principles and practice. Philadelphia: Belfus Press, 1999.

  74. Harker LA, Malpass TW, Bronson NE. Mechanisms of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood 1980;56:824-839.

  75. Weerasinghe A, Taylor KM. The platelet in cardiopulmonary bypass. Ann Thorac Surg 1998;66:2145-2160.

  76. Weiss HJ. Antiplatelet drugs: pharmacological aspects. En: Platelets: Pathophysiology and antiplatelet drug therapy. New York: Alan R. Liss, 1982:45.

  77. Triplett DA. Appendix C: Miscellaneous lists and forms. En: Triplett DA, Ed. Platelet function evaluation: laboratory evaluation and clinical application. Chicago: ASCP Press, 1978:291.

  78. Rao AK, Walsh PN. Acquired qualitative platelet disorders. Clin Haematol 1983;12:201-222.

  79. Amezcua JL, Parsons A, Moncada S. Unstable metabolites of arachidonic acid, aspirin and the formation of the hemostatic plug. Thromb Res 1978;13:477-480.

  80. Weksler BB, Pett SB, Alonso D, et al. Inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med 1983;308:800-809.

  81. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low dose aspirin in healthy subjects. J Clin Invest 1982;69:1366-1383.

  82. Preston FE, Greaves M, Jackson CA. Cumulative inhibitory effect of daily 40 mg aspirin on prostacyclin synthesis. Lancet 1982;1:1211-1220.

  83. Yamauichi K, Furui H, Taniguchi N. Effects of diltiazem hydrochloride on cardiovascular response, platelet aggregation and coagulation activity during exercise testing in systemic hypertension. Am J Cardiol 1986;57:609.

  84. Hines R, Barash PG. Infusion of sodium nitroprusside induces platelet dysfunction in vitro. Anesthesiology 1989;70:611.

  85. Hines R. Preservation of platelet function during trimethaphan infusion. Anesthesiology 1990;72:834.

  86. Bick RL, Fekete LF. Cardiopulmonary bypass hemorrhage: aggravation by pre-op ingestion of antiplatelet agents. Vasc Surg 1979;13:227.

  87. Leist ER, Banwell JG. Products containing aspirin. N Engl J Med 1974;291:710-722.

  88. Selner JC. More aspirin-containing drugs. N Engl J Med 1975;292:372-378.

  89. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994;330:956.

  90. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997;336:1689.

  91. Kereiakes, DJ, Kleiman, NS, Ambrose, J, et al. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol 1996;27:536.

  92. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation 1997;96:1445.

  93. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med 1998;338:1498.

  94. Sabatine, MS, Januzzi, JL, Snapinn, S, et al. A risk score system for predicting adverse outcomes and magnitude of benefit with glycoprotein IIb/IIIa inhibitor therapy in patients with unstable angina pectoris. Am J Cardiol 2001;88:488.

  95. Cohen, M, Gensini, GF, Maritz, F, et al. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial. J Am Coll Cardiol 2003;42:1348.

  96. Dasgupta, H, Blankenship, JC, Wood, GC, et al. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/ IIIa receptor inhibitors: A pooled analysis. Am Heart J 2000;140:206.

  97. Blankenship, JC, Tasissa, G, O'Shea, JC, et al. Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT trial. J Am Coll Cardiol 2001;38:653.

  98. Hollopeter, G, Jantzen, HM, Vincent, D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001;409:202.

  99. Angiolillo, DJ, Capranzano, P. Pharmacology of emerging novel platelet inhibitors. Am Heart J 2008;156:S10.

  100. Sinzinger H, Kaliman J, O’Grady J. Platelet lipoxygenase defect (Wein-Penzing defect) in two patients with myocardial infarction. Am J Hematol 1991;36:202.

  101. Holliday PL, Mammen E, Gilroy J. Sticky platelet syndrome and cerebral infarction in young adults. En: 9th International Joint Conference on Stroke and Cerebral Circulation. Phoenix: 1983 (abst).

  102. Rubenfire M, Blevins RD, Barnhart MI, et al. Platelet hyperagregability in patients with chest pain and angiographically normal coronary arteries. Am J Cardiol 1986;57:657.

  103. Mammen EF, Barnhart MI, Selik NR, et al. “Sticky platelet syndrome”: A congenital platelet abnormality predisposing to thrombosis. Folia Haematol 1988;115:361.

  104. Hayward CP, Pai M, Liu Y, et al. Diagnostic utility of light transmission platelet aggregometry: results from a prospective study of individuals referred for bleeding disorder assessments. J Thromb Haemost 2009;7:676.

  105. Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009;53:849.

  106. Solis RT, Wright CB, Gibbs MB. Electronic particle size measurements of platelet aggregates formed in vitro. J Appl Physiol 1975;38:739.

  107. Ozaki, Y, Satoh K, Yatomi Y, et al. Detection of platelet aggregates with a particle counting method using light scattering. Anal Biochen 1994;218:284.

  108. Yamamoto T, Egawa Y, Shirasawa Y, et al. A laser light scattering in situ system for counting aggregates in blood platelet aggregation. Meas Sci Technol 1995;6:174.

  109. Eto K, Takeshita S, Ochiai M, et al. Platelet aggregation in acute coronary syndromes: use of a new aggregometer with laser light scattering to assess platelet aggregability. Cardiovasc Res 1998;40:223.

  110. Coller BS, Lang D, Scudder LE. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIA receptor blockade. Circulation 1997;95:860.

  111. Smith JW, Steinhubl SR, Lincoff AM, et al. Rapid plateletfunction assay: and automated and quantitative cartridgebased method. Circulation 1999;99:620.

  112. Cattaneo M, Hayward CP, Moffat KA, et al. Results worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH. J Thromb Haemost 2009;7:1029.

  113. Jennings I, Woods TA, Kitchen S, Walker ID. Platelet function testing: practice among UK National External Quality Assessment Scheme for Blood Coagulation participants, 2006. J Clin Pathol 2008;61:950.

  114. Quiroga T, Goycoolea M, Matus V, et al. Diagnosis of mild platelet function disorders. Reliability and usefulness of light transmission platelet aggregation and serotonin secretion assays. Br H Haematol 2009;147:729.

  115. Born GV, Hume M. Effects of the numbers and sizes of platelet aggregates on the optical density of plasma. Nature 1967;215:1027.

  116. Frojmovic MM, Milton JG, Duchastel A. Microscopic measurements of platelet aggregation reveal a low ADPdependent process distinct from turbidometrically measured aggregation. J Lab Clin Med 1983;101:964

  117. Thompson NT, Scrutton MC, Wallis RB. Particle volume changes associated with light transmittance changes in the platelet aggregometer: dependence upon aggregating agent and effectiveness of stimulus. Thromb Res 1986;41:615.




2020     |     www.medigraphic.com